TEAM is live. Here’s what an administrator actually does about it.

The debate about whether value-based joint replacement would arrive is over. TEAM — CMS’s mandatory episode model — is live, and for the facilities inside it, every lower-extremity joint replacement now carries a 30-day episode window in which cost, complications, and outcomes are scored against a peer curve. There is no opt-in and no sitting out: the reconciliation math happens whether or not anyone in the building is watching it.

The administrator’s real problem

Most centers experience the mandate as paperwork. The actual event is financial: your episodes are being priced against your region’s, and the difference between the right side and the wrong side of that curve is money the center either keeps or returns. Two drivers dominate the spread:

• Revisions and complications. Roughly one in five standard knee-replacement patients report they aren’t fully satisfied — and dissatisfaction correlates with alignment and fit. Every revision inside the window is an episode blown.
• What happens after discharge. The window doesn’t close at the door. Readmissions, ED visits, and slow recoveries in the 30 days at home land on your score.

The four-item checklist

• Know your curve position. Pull your episode spend and revision rate against regional benchmarks. If you can’t produce this number in a week, that’s the first fix.
• Make personalization a line item, not a philosophy. Patient-specific planning and implant fit exist today and attack the dissatisfaction driver directly. Price it per case against what a single revision costs you inside the window.
• Instrument recovery. If the 30 days at home are invisible to you, you are being scored on something you can’t see. Remote tracking (RTM) both closes that gap and reimburses (~$147/mo per monitored patient*).
• Capture outcomes registry-grade. AJRR + PROMs, on every case — because under two-sided risk, an outcome you can’t prove is an outcome you don’t get paid for.

Where MSKvalue fits

MSKvalue assembles exactly this stack — personalized surgery, registry-grade outcome capture, monitored recovery, and the billing layer that gets the value paid — as one accountable episode rather than a pile of point tools. For ASCs the economics are deliberately capital-light: free to plan, pay-per-case, no capital wall.

Figures marked * are illustrative and program-dependent; not clinical, legal, or financial advice. MSKvalue assembles independent best-of-class products with the American Joint Replacement Registry as the outcomes backbone.